Background Lupus nephritis (LN) is one of the major complications associated with Systemic Lupus Erythematosus (SLE).
Activated leukocyte cell adhesion molecule (ALCAM or CD166) is a promising urine biomarker that binds to CD6, a receptor
found on lymphocytes. This binding results in T-cell activation, proliferation, and recruitment, which causes tissue infammation and may explain the pathophysiology of LN.
Aim of work Investigate the urinary ALCAM level in SLE, study its relationship to disease activity, and clarify the association with LN activity and histopathology.
Patients and methods A case–control study was performed on 60 patients with SLE and 20 matched controls. The SLE
disease activity index (SLEDAI) and the activity of renal disease (rSLEDAI) were evaluated. Renal biopsy and uALCAM
levels were also investigated.
Results Urinary ALCAM levels were higher signifcantly in active LN patients than inactive LN patients, active and inactive
non-LN SLE, and the control group (p